Liz Highleyman

An oncolytic virus that kills cancer cells and triggers immune responses against tumors shows promise for children with brain cancer.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

The CDC and FDA confirmed that the vaccine is safe, and said the recent pause should be lifted for all groups.

The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.

Studies have shown an alarming drop in screenings—and more advanced cancer—during the COVID-19 pandemic.

The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.

The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.

More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.

The kinase inhibitor delayed disease progression by 27% for people who had tried at least two prior therapies.

Study participants who received Libtayo had a 31% lower risk of death than those treated with chemotherapy.

COVID-19 cases, hospitalizations and deaths continue to drop in the United States, but a global pandemic cannot be defeated in one country.

The protein vaccine was 96% effective against the original SARS-CoV-2 coronavirus, but less so against new variants.

An inside look at five research developments that have the potential to transform the treatment of cancer

COVID-19 vaccine’s mRNA technology could one day help treat cancer.

The COVID-19 vaccines are safe and should be effective even for people with advanced cancer.